PMC:7571312 / 680-1172
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T8747 | 14-21 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T8 | 138-142 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T9 | 451-459 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T9960 | 32-33 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T99506 | 55-62 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focused |
| T95582 | 313-314 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T3 | 14-21 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T4 | 111-117 | Chemical | denotes | ketone | http://purl.obolibrary.org/obo/CHEBI_17087 |
| T5 | 124-134 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T6 | 166-172 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
| T7 | 297-299 | Chemical | denotes | PF | http://purl.obolibrary.org/obo/CHEBI_74795|http://purl.obolibrary.org/obo/CHEBI_90284 |
| T9 | 322-331 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T10 | 362-376 | Chemical | denotes | pharmaceutical | http://purl.obolibrary.org/obo/CHEBI_52217 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 32-262 | Sentence | denotes | A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. |
| T7 | 263-460 | Sentence | denotes | Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19. |
| T8 | 462-474 | Sentence | denotes | Introduction |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 25 | 138-146 | Species | denotes | SARS CoV | Tax:694009 |
| 26 | 335-340 | Species | denotes | CoV-2 | Tax:2697049 |
| 27 | 111-117 | Chemical | denotes | ketone | MESH:D007659 |
| 31 | 451-459 | Disease | denotes | COVID-19 | MESH:C000657245 |